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Conventional echocardiographic parameters are currently used in determining the timing 
for surgery in patients with mitral regurgitation. Since brain natriuretic peptide (BNP) rises 
in response to ventricular muscle stretch, and is to detect early heart failure, we 
hypothesized that BNP would be activated in patients with regurgitant valvular heart 
disease and concomitant left ventricular dilatation. 
Aim/Objectives: 
We therefore studied the pattern of changes in NT -pro BNP in patients with chronic severe 
rheumatic mitral regurgitation who were undergoing mitral valve replacement and 
compared this with the newer modality of tissue Doppler imaging (TDI). 
Setting: 
Patients submitted to surgery were prospectively evaluated over 8 months at Inkosi Albert 
Luthuli Central Hospital, Department of Cardiology. Controls were obtained from the 
outpatients' follow-up clinic. 
Methods: 
Simultaneous quantification of the severity of mitral regurgitation (MR), left ventricular 
(LV) end systolic volume (ESV), left atrial (LA) volume and Doppler filling ratios (mitral 
(E)/annulus (Ea)) were performed at baseline in all patients and was repeated at 1-week 
and at the six-week follow-up visit in surgical patients. 
v 
Results 
Both groups were similar for age and gender and echo-Doppler parameters in all patients 
preoperatively except LA size (p< 0.01) and volume (p<0.004) which were more elevated 
in the surgical group. Mean NT -pro BNP levels were markedly elevated preoperatively 
(262 pmolll) in all surgical cases compared to controls (57 pmol/l; p=O.OOOl). NT-pro 
BNP levels increased further at one week post surgery (395pmol/l) and subsided at the six 
week follow-up visit (94 pmol/I).These changes were accompanied by significant 
reduction in LA (p= 0.003) and LV chamber dimensions (EDD = 0.004) with an increase 
in the ejection fraction from 42% at one week to 52 % at six weeks. Four patients had 
abnormally elevated NT -pro BNP levels (>53pmol/l) at the 6-week follow-up visit. A 
ROe curve was constructed for all variables to separate surgical cases from controls. The 
area under the curve was highest for NT -pro BNP (sensitivity= 96%, specificity 45 %). 
Conclusion 
1. There was a significant difference in the left atrial chamber size and volume, as well 
as Em/Ea (TDI) and NT-proBNP levels preoperatively between the two groups. The 
lack of a significant difference in the LV parameters between surgical and control 
groups suggest an almost total reliance on symptoms in deciding the timing of 
surgery which was reflected by markedly elevated NT -pro BNP in all surgical 
patients. 
2. Postoperatively, there was a significant reduction in LA and LV dimensions. 
3. The high false positivity rate for NT-pro BNP suggests that the test is most likely 
reflecting early LV decompensation in the less symptomatic control patients who 
rightly need surgery. 
VI 
4. Tissue Doppler indices had similar sensitivity but low specificity compared to 
NT-proBNP. 
5. Serial estimations of NT-pro BNP may prove useful in selecting patients for 
surgery. 
vu 
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Valvular insufficiency may generally be classified as organic when it is due to intrinsic 
damage to the valve apparatus, or functional when the valve itself is structurally normalL but 
the regurgitation is due to dilatation of the annulus that prevents leaflet apposition. Whereas 
organic mitral regurgitation (MR) in the Western world is due to valve prolapse or ischaemic 
heart diseasel rheumatic heart disease (RHD) continues to be a predominant cause of 
morbidity in developing countries. RHD results from organization of the endocardial lesions 
of acute rheumatic fever. Subsequent scarring from the inflammatory process results in 
deformation of the valve, and with repeated infection there is progressive valvular damage. 
The mitral valve is almost always involved in chronic rheumatic valvular disease. The 
macroscopic hallmark of post-rheumatic valvular disease is commissural fusion associated 
with leaflet fibrosis. Chronically, scarring of the valve leaflets leads to MR, due to shortening 
and increased rigidity of the valve leaflets, in combination with shortening and fusion of the 
valve chordae. These changes lead to inadequate leaflet coaption and apposition. In its early 
stages valvular regurgitation is without symptoms. At some stage in the natural history of 
severe regurgitation the clinician has to decide on the need for operation. 
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1.1. Natural history of Mitral Regurgitation 
As indicated above, patients with MR may remain asymptomatic for many years, with an 
average time from diagnosis to symptoms of 16 years2. Once symptoms supervene, outcome 
is improved with surgical intervention compared to medical therapy, with a reported survival 
of only 33- 45% at 5 years without surgical intervention 3; 4. It is well established that some 
patients with asymptomatic severe MR may develop irreversible contractile dysfunction 
which is often masked by the after load reducing effect of the regurgitant lesions. Few data 
are available on the rate of haemodynamic progression of regurgitation severity, the rate of 
left ventricular (L V) dilatation, or the natural history of patients with mild to moderate 
regurgitation. 
In a study of74 patients with primary MR of varying aetiology .. the severity ofMR showed a 
mean annual increase of 7.4 ml in regurgitant volume, 2.9% in regurgitant fraction and 
0.06cm2 in regurgitant orifice area 6. Independent predictors of rapid progression included a 
new flail leaflet and an increase mitral annulus diameter suggesting changes in the valve 
anatomy contribute significantly to disease progression. 
Widely disparate estimates of long term survival in patients with mitral regurgitation between 
7-27% at five years have been reported 4, 7. Patients with severe MR have a mortality rate of 
5% annually. In patients with asymptomatic prolapse and severe MR, there is a 10.3% annual 
risk of developing surgical indications 8. Most deaths are related to Heart failure (HF), but 
sudden death has been reported in 5% of patients, even in the absence of severe LV 
dysfunction, suggesting that arrhythmias may also be an important mechanism of events. 
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Patients with mild-moderate MR have a much lower rate of cardiac event with a 
five year event free survival of >95% for those with mild MR, 85% for moderate 
9 MR compared to 70% for severe MR . 
In comparison to the expected survival, Ling et al showed that an excess mortality 
was noted (6.3% yearly) in the natural history of mitral regurgitation caused by 
flail leaflets 10. They showed that conservative management was associated with 
high morbidity: ten years after diagnosis, 90% of their patients were either dead or 
had undergone surgery. A high morbidity was also present with a 10 year 
incidence of atrial fibrillation of 30%, and of heart failure of 63%. Furthermore, at 
10 years almost 90% of patients were either dead or had undergone surgery, 
which means that the valve surgery was almost unavoidable. Patients with New 
York Heart Association (NYHA) functional class III or IV symptoms, even 
transient, displayed a considerable mortality (34% yearly) if not operated upon, 
but even those in class I or II had a notable mortality (4.1 % yearly). Patients with 
ejection fraction < 60% also displayed an excess mortality as compared to those 
with ejection fraction 2: 60%, but no group at very low risk under medical 
treatment could be defined. 
Sudden death is a catastrophic event, responsible for approximately a quarter of 
the deaths occurring under medical treatment. A study of sudden death by 
Grigioni F et al in 348 patients with mitral regurgitation showed that sudden death 
occurs at a rate of 1.8% per year overall ll . The predictors of sudden death were 
ejection fraction, symptoms, and atrial fibrillation. 
While, the determinants of higher rates of sudden death are mostly severe 
symptoms and reduced ejection fraction, Grigioni found that even in patients 
without these risk factors, the rate of sudden death was 0.8% per year. 
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These data underscore the serious prognostic implications of severe mitral regurgitation, 
suggesting that surgery should be considered timeously in the course of the disease in order 
to avoid events and assure a successful long term outcome. In particular, they emphasise the 
need for data in uniform populations of MR where inferences can be made about criteria for 
surgical intervention in pure uncomplicated MR in the absence of confounding elements that 
affect the disease progression. Therefore careful evaluation of the patient with MR is critical 
in determining the need for medical therapy and the timing of surgery. A study of the timing 
of surgery in patients with rheumatic MR in a population of subjects with low risk for 
accompanying ischaemic heart disease will provide such information. 
1.2. Pathophysiology of Mitral Regurgitation 
Mitral regurgitation produces volume overload of the left ventricle and left atrium. If the 
mitral regurgitation develops slowly over months to years, or if the acute phase can be 
managed with medical therapy, the individual will enter the chronic compensated phase of 
the disease. The left ventricle develops eccentric hypertrophy as a result of sarcomere 
elongation. Preload increases and the left ventricle dilates in order to maintain a normal 
forward flow. The increase in afterload resulting from left ventricular dilatation is offset by 
the fact that the ventricle is pumping much of its volume (regurgitant volume) into a low-
impedance circuit (the left atrium). Therefore, afterload may be variably reduced initially in 
MR and typically only becomes elevated in later stages of the disease. An individual may be 
in the compensated phase of mitral regurgitation for years, but will eventually develop left 
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ventricular dysfunction, the hallmark for the chronic decompensated phase of mitral 
regurgitation. It is currently unclear what causes the decompensated phase of this disease. 
In the decompensated phase, the ventricular myocardium is no longer able to contract 
adequately to compensate for the volume overload of mitral regurgitation, and the stroke 
volume of the left ventricle decreases. The decreased stroke volume causes a decreased 
forward cardiac output and an increase in the end-systolic volume. The increased end-systolic 
volume translates to increased filling pressures in the ventricle and the atrium with resultant 
pulmonary venous congestion. The individual may then develop symptoms of congestive 
heart failure. With increasing ventricular dilatation, the mitral valve annulus becomes more 
spherical and dilated, and the degree of mitral regurgitation worsens. 
As pointed out, with chronic MR, contractile dysfunction may occur early in the disease 
course, often before the onset of disease symptoms. Ventricular decompensation is 
characterized by an increase in the end-diastolic dimension (EDD) and end-systolic 
dimension (ESD). The ejection fraction (EF) declines, but may still remain in the normal 
range, making recognition of the onset of contractile failure more difficult. Thus, ejection 
indices such as ejection fraction are not considered reliable measures of left ventricular 
contractile function since they remain in the normal range when contractility is already 
impaired. It has been shown that load-independent measures of contractile function, such as 
elastance, are more reliable. However, these measurements are both time consuming and 
invasive to perform and are therefore of limited clinical relevance in patient follow-up 11. 
Given its limitations, the EF <60% has been shown to be associated with poorer survival after 
corrective surgery and likely indicates covert contractile dysfunction in MR patients 13. 
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Mitral regurgitation enlarges the left atrium (LA), which increases atrial compliance enough 
to normalise the left atrial pressure, even in the presence of severe regurgitation. Therefore 
most patients are asymptomatic at diagnosis 14. Other factors include transmission of the 
kinetic energy of the mitral regurgitant jet to the left atrial wall and atrial fibrillation 15; 16, 
followed eventually by changes in the pulmonary circulation 17. Atrial fibrillation is also 
associated with adverse cardiovascular and survival end pointsl8 . Chronic MR leads to 
elevated pulmonary pressures due to passive elevation in the pulmonary venous pressure. 
With longstanding disease some patients develop superimposed reactive pulmonary 
hypertension that becomes irreversible because of the progressive histological changes in the 
pulmonary vasculature 16. Pulmonary hypertension ultimately leads to RV dilatation and 
systolic dysfunction, often in association with tricuspid regurgitation due to the dilated 
tricuspid annulus. 
1.3. Development of Symptoms in Mitral Regurgitation 
Symptoms often occur late in chronic MR, most likely as a result of the compliance 
properties of the left atrium that allow it to accommodate large volumes of blood without a 
significant rise in pressure. In some instances, pulmonary pressures increase, and although 
this is associated with poorer survival, it may also protect against the deVelopment of 
symptoms. Cardiac biomarkers such as cytokines and B-type natriuretic peptides, which are 
reported to be elevated in congestive heart failure, are also increased in patients with chronic 
MR and cardiac dysfunction. Contractile dysfunction may precede symptoms, and therefore 
evaluation of symptoms alone is inadequate in determining the timing of surgery in chronic 
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MR. Delaying surgery until symptoms appear is problematic since the outcome may be sub-
optimal at that stage, with excess risk of postoperative mortality and LV dysfunction. 
1.4. Compensatory Mechanisms and the development of contractile dysfunction 
in Mitral Regurgitation 
Compensatory mechanisms for chronic MR include the development of catecholamine 
excess 17 , which may also play a role in the genesis of arrhythmias and may explain sudden 
death that has been reported in patients with longstanding severe MR who are managed 
without surgery 11. Studies in asymptomatic patients with severe MR demonstrate the high 
likelihood of symptoms and risk of sudden· death within 10 years of diagnosis and the almost 
inevitable need for surgery 19.The onset of symptoms and LV impairment heralds an 
extremely poor prognosis, with an annual mortality of 34% for those in New York Heart 
Association functional class III or IV. 
The development of contractile dysfunction and its relation to the severity of volume 
overload in MR is not clearly understood. What is clear is that prolonged contractile 
dysfunction is eventually irreversible even after the MR is relieved and is predictive of both 
death and congestive heart failure 12• A number of studies suggest that left ventricular size, 
particularly in end-systole, is predictive of outcome, presumably mediated through a 
reduction in left ventricular contractility. A recent study from the Mayo Clinic showed a 
close link between the quantitative severity of MR and adverse outcome in conservatively 
managed patients, suggesting that this effect may be mediated through volume loading 20. It 
has also been shown that patients with the most dilated ventricles preoperatively are least 
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likely to regain contractile function even after successful corrective mitral valve surgery. In a 
series of experiments in which high-fidelity measures of left ventricular contractility such as 
elastance were used, it was shown that left ventricular contractile dysfunction is present in 
many patients with severe MR despite a normal ejection fraction and that this returned to 
normal after corrective mitral valve surgery in some but not all patients 21. Therefore, when 
contractile dysfunction occurs, it may be temporary or reversible if detected and treated in 
time. The duration and determinants of this window of opportunity are not known 12. 
1.5. Timing of surgical intervention in MR 
Left ventricular dysfunction is a major determinant of poor outcome in MR irrespective of 
whether treatment is medical or surgical. It is the most frequent cause of late death after 
surgery6. A large study of the outcome of mitral surgery for mitral regurgitation analysed 
ejection fraction as a function of preoperative left ventricular function4. Despite its 
limitations, ejection fraction was the best predictor of long term survival. As the best 
outcome is observed in patients with an ejection fraction ~ 60%, it would appear prudent to 
operate as soon as the EF approaches 60%. 
Recent studies recommend elective surgery early rather than late in patients with severe MR 
20,22. A drawback of both of these studies is that patients were managed by their individual 
physicians, and it is unclear how frequently they were evaluated or what criteria were used to 
determine when surgical intervention was appropriate. Although the information in these 
studies is important and compelling regarding the poor outcome associated with chronic MR 
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when treated conservatively, it does not necessarily provide us with a comprehensive 
evaluation of the effectiveness of the current guidelines. 
1.6. Current measures of Global Systolic Function 
Echocardiography is the most commonly used nonmvaSlve method for assessment and 
estimation of LV function. It provides a good clinical estimate of left ventricular systolic 
function but its chief limitation lies in the evaluation of contractile function in mitral 
regurgitation since ejection fraction is often maintained in the presence of L V dysfunction. It 
is noteworthy that most sudden deaths occur in asymptomatic patients with normal LV 
function. Furthermore, other limitations include overestimation of the degree of MR and the 
high interuser variability, particularly in the detection of the subtle early changes of LV 
impairment. 
So, although numerous echocardiographic techniques, both qualitative and quantitative been 
developed, no single precise method is routinely used as a "reference standard" 23 and 
previous studies have demonstrated that existing measures of MR severity correlate poorly 
with clinical signs and symptoms. There are few data on the newer echocardiographic 
modalities, notably Doppler tissue imaging, the predictive values of which has not been 
determined. 
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1.7. New Markers of LV dysfunction 
1.7.1. Tissue Doppler Imaging 
Current image acquisition from the parasternal short and long axis view allows assessment of 
myocardial velocity resulting from radial fiber contraction. During systole basal and mid 
segments are moving not only inwards but also longitudinally towards a center of gravity, 
which is located between the second and third part of the long axis 24, 25. Contraction of 
subendocardial longitudinal fibers can be reliably assessed by Tissue Doppler Imaging (TDI) 
from the apical views. From base to apex, a velocity gradient with highest velocities at basal 
segments can be observed; apical segments thicken during contraction while the epicardial 
apex remains relatively stationary. 
Tissue Doppler Imaging has been evaluated in different patient groups for assessment of the 
ejection fraction. Left ventricular long axis contraction is reflected in mitral annular descent, 
which can be evaluated by TDI at different sites. In comparison with radionuclide 
ventriculography the septal and lateral average velocities were well correlated with the 
ejection fraction under identical conditions. A six-site peak mitral annular descent velocity of 
>5.4 cm/s identified the ejection fraction within normal range with reasonable sensitivity and 
specificity 25. However, as for the ejection fraction it has to be taken into account that mitral 
annulus-TDI velocities are dependent on loading conditions, atrial haemodynamics and heart 
rate as well. Yamada et al found significant positive correlations of endocardial peak systolic 
velocity for the L V posterior wall with FS and the ejection fraction in different patient groups 
but no correlation between Fractional shortening (FS) or the ejection fraction and peak 
velocity of the ventricular septum 27. The diastolic filling pattern by TDI very closely 
resembles the mitral inflow E and A pattern and the E'/A'ratio is quite similar to the E/A 
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ratio. With normal LV filling early (E') diastolic velocity range is > 10 cmls in the young and 
> 8 cmls in the older patient, late diastolic velocities (A') increase with age. 
While the mitral inflow very much depends on preload, thus contributing to problems of 
interpretation, diastolic tissue velocities are far less influenced by these parameters. 
Tissue Doppler Imaging is also useful in the detection of impaired left ventricular relaxation 
and estimation of filling pressure in patients with atrial fibrillation. In these patients both 
conventional mitral and pulmonary Doppler indices are limited because of the altered atrial 
pressure and loss of synchronized atrial contraction. The EIE' ratio correlated with left 
ventricular filling pressures. The EIE' ratio of 2: 11 predicted left ventricular filling pressures 
2: 15 mmHg with a sensitivity of 75 % and a specificity of 93%.TDI provides reproducible 
and complementary measures of left ventricular relaxation and filling pressures, which allow 
a more comprehensive evaluation of diastolic function28. 
1.7.2 Brain Natriuretic Peptide 
B-type natriuretic peptide (BNP) and its inactive N-terminal fragment (NT-proBNP) are 
neurohormones synthesized and secreted mainly from ventricular myocardium. Stimulus for 
their release is an increase in ventricular wall stress, ventricular volume expansion and 
pressure overload. Plasma levels of the natriuretic peptides are elevated with LV systolic 
dysfunction after myocardial infarction (MI) and are independent prognosticators 29. We 
hypothesized that NT -pro BNP levels would be increased in mitral regurgitation, and because 
this is a validated diagnostic test in heart failure, we were hopeful that it could prove to be an 
early marker for the development of LV dysfunction. 
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Previous studies have shown that BNP is an independent predictor of high LV end-diastolic 
pressure and for assessing mortality risk in patients with congestive heart failure (CHF) 30. 
BNP levels rise with age 31. Mean BNP levels are 26.2 +/- 1.8 pg/mL in the group aged 55-64 
years, 31.0 +/- 2.4 pglmL for the group aged 65-74 years, and 63.7 +/- 6 pglmL for the group 
aged 75 years and older. Additionally, women without CHF tend to have somewhat higher 
BNP levels than their male cohorts of the same age, with women 75 years and older having a 
mean BNP level of 76.5 +/- 3.5 pg/mL. Although the reason is unknown, aging women 
possibly have stiffer ventricles than age-matched men. 
In the emergency room, BNP testing is helpful in the evaluation of acute CHF. To rule out 
acute CHF, the cut-point of 300pg/ml had a negative predictive value (NPV) of 98%. To rule 
in acute HF, age-related cut-points of 450, 900 and 1800pglml for ages <50 years, 50-75 
years and> 75 years were defined as an optima strategy 32. BNP levels on admission were the 
strongest independent predictor of death after 60 days follow-up. 
BNP levels also correlate highly with the change in PCWP pressure 33. It has been proposed 
that BNP levels may be a useful surrogate indicator of PCWP, although this is not common in 
clinical practice. BNP may help in tailoring treatment of the decompensated patient. 
Furthermore, in heart failure and coronary disease, BNP level reflects the magnitude of 
hemodynamic and L V alterations and predicts outcome, is linked to the presence of 
functional MR, and is a major biomarker of risk, so that BNP measurement was recently 
recommended as integral to clinical management 34. 
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In chronic organic MR, NT -proBNP physiological determinants and outcome implications 
are undefined. It remains unclear whether NT -proBNP purely reflects the symptoms, MR 
severity or whether it is a biomarker of ventricular and atrial alterations due to the MR. 
These biomarkers offer an opportunity for the detection of early LV dysfunction and may be 
useful in identifying high-risk patients. It is possible that natriuretic peptide testing in patients 
with MR will add to the information obtained from echocardiography, but to date there are 
only limited published data 35. 
1.8. Statement of the problem 
Although the aetiology and mechanism of mitral regurgitation are critical factors for the 
management of patients with severe chronic mitral regurgitation, the left ventricular function 
is the most powerful predictor of long-term prognosis and the main factor for determining the 
timing for surgery. 
The ejection fraction and end-systolic dimension (ESD), which are echocardiographic 
parameters, as well as the development of symptoms, have been proposed as the best 
predictors of long-term mortality. Either an EF <60% or and ESD > 45mm are considered the 
cut-off values for demonstrating covert LV dysfunction and should be immediately 
considered as an indication for surgery. This approach however, has inherent limitations, 
since ejection fraction is often maintained during the compensated phase of chronic MR 
when L V dysfunction develops with minimal or absent symptoms. Furthermore, when LV 
dysfunction does develop, the EF may fall, but remains within normal limits due to a reduced 
afterload from the runoff into the left atrium. Also, an LV ESD > 45mm is rarely seen in the 
less symptomatic patients. 
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So, although numerous echocardiographic techniques, both qualitative and quantitative, have 
been developed, there is no wide consensus on how to measure intrinsic left ventricular 
function in mitral regurgitation, and previous studies have demonstrated that existing 
measures of MR severity correlate poorly with clinical signs and symptoms. 
So the critical question remains: Is there a load independent parameter that can predict the 
development of, or detect early LV dysfunction? 
1.9. Hypothesis 
We hypothesized that patients with worsening mitral regurgitation and/ or left ventricular 
dysfunction have greater activation of NT -pro BNP compared to a control MR population of 
stable subjects with severe regurgitation. 
1.10. Aims 
1. To perform standard assessment of the severity of MR using clinical symptoms, 
ventricular dimensions and Doppler echocardiography 
2. To compare standard assessment with tissue Doppler parameters (obtained at 
echocardiography) in defining the severity ofMR. 
3. To determine which parameters (NT-proBNP, TDI, ESD) are predictive of early 
cardiac decompensation 
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4. To compare these pre-surgery parameters, with post-surgery values and clinical 
outcomes. 
5. To identify high risk patients (as defined by post-surgery outcomes) and cut-off 
values for the timing of surgery 
15 




Ethics approval was given by the Biomedical Research Ethics administration at the University of 
KwaZulu-Natal, Nelson R Mandela School of Medicine in November 2006. Reference No. 
H112/06. Informed consent was obtained from all subjects (see Appendix 1). 
2.2. Study Setting 
The study population was selected from Inkosi Albert Luthuli Central Hospital, and included all 
consecutive patients undergoing surgical correction for mitral regurgitation, as well as all 
patients with severe MR followed up at the cardiology outpatient clinic. 
2.3. Design 
The study enrolled patients prospectively during Nov 2006-Sept 2007. Patients with severe, 
chronic, isolated MR underwent comprehensive quantitative Doppler echo cardiography 
performed by one trained ultrasonographer (RP). Patients were excluded if they had acute MR, 
MR due to ischaemic heart disease or CMO, previous valve surgery and associated aortic or 
congenital valve disease. Patients with associated mitral stenosis were excluded if the valve area 
was less than 2.0cm2. Clinical evaluation and management of the patients were conducted by 
their independent clinicians. Assessment of symptoms was determined clinically by the NYHA 
classification and Atrial fibrillation (AF) was diagnosed by electrocardiography. Doppler 
echocardiographic recordings and blood samples were collected simultaneously and estimation 
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of the NT -proBNP level processed independently. The ultrasonographer was blinded to the 
results of the NT -proBNP and clinical examination. Control subjects with severe MR were 
selected from the cardiology outpatient follow-up clinic where they were assessed as not 
requiring surgery in the short term and were receiving medical therapy. Controls were selected as 
severe MR, but without evidence of ischaemic heart disease (1 patient was found to have 
ischaemic MR) as it is known that NT-proBNP is activated in the presence of ischaemia. The 
majority of patients, both in the study and control groups, were receiving diuretic and converting 
enzyme inhibitor therapy. 
2.4 Method: Evaluation of MR 
2.4.1. Echocardiographic recordings 
Colour Doppler echo cardiography was performed on all patients using a Siemens Sequoia 
machine (Acuson, Germany) with phased array transducer and an emission frequency of 3.0 
megaHertz with the patient in the left decubitus position. The images and measurements were 
reviewed off-line by a trained cardiologist. 
2.4.2. Calculation of chamber dimensions 
The LV end-systolic and end-diastolic dimensions, LV wall thickness, and left atrial (LA) 
dimensions were measured according to American Society of Echocardiography guidelines using 
the leading edge method 36. All measurements were averaged from three to five cardiac cycles. 
The LA volume was estimated using the biplane ellipsoid formula 36, The LV end-systolic and 
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end-diastolic volumes and EF were measured from the apical four-chamber view using the 
modified Simpson's method 36. 
2.4.3. Measurement of the dP/dT 
The rate of increase in ventricular pressure III early systole (dP/dt) reflects ventricular 
contractility. A dP/dt less than lOOOmmHg/sec is indicative of impaired ventricular contractility. 
The dP/dt derived from the continuous-wave Doppler spectrum of the mitral regurgitationjet was 
determined as follows: the two points on the MR spectrum corresponding to 1 m1s and 3 m1s 
were identified. These points corresponded to LV-left atrial pressure gradients of 4 mm Hg and 
36 mm Hg using the modified Bemoulli equation (P = 4v2). Doppler-derived dP/dt was defined 
as ~P/~t = 36-4/~t = 32 mm Hg/~t 37. (See below) 
Figure 1: Continuous wave Doppler measurement of dP/dT 
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2.4.4. Assessment of severity of mitral regurgitation 
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The six frequently applied echocardiographic variables described by Thomas et al 38 were used to 
evaluate MR. Three of the variables are significantly influenced by the severity of MR; these 
included jet penetration into the LA, Proximal isovelocity surface area (PISA), Continuous wave 
(CW) regurgitant jet character and intensity. The other three variables related to the 
compensatory changes in the heart secondary to MR: pulmonary artery pressure by tricuspid 
regurgitation velocity, pulmonary venous inflow pattern and LA size. Mitral regurgitation was 
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quantified by measurement of the regurgitant volume and fraction, as well as the effective orifice 
area using PISA. 
2.4.4.1 Calculation of regurgitant volume and fraction 
Quantitative Doppler echocardiography is based on the measurement of the mitral and aortic 
stroke volumes 38. Forward stroke volume (Figure 2) in patients with MR was calculated as the 
product of the left ventricular outflow tract velocity time integral and the LVOT area (regurgitant 
volume = MV stroke volume - forward stroke volume; Regurgitant fraction (RF) = Regurgitant 
volume/forward stroke volume). 
Figure 2: Calculation of the regurgitant volume 
According to published guidelines severe MR corresponds to a regurgitant volume >60ml/beat 39. 
2.4.4.2 Measurement of Effective orifice area (EROA) 
The proximal isovelocity surface area was measured by using proximal flow convergence 
method
40 
and was used to determine the flow rate across the mitral orifice (Figure 3). 
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Dividing peak flow rate (2IT rv) by the maximal velocity through the mitral orifice (obtained by 
continuous-wave Doppler) yields the regurgitant orifice area (ROA), the actual size of the "hole" 
in the valve and the most fundamental quantitative parameter of severity of regurgitation. An 
effective orifice area of 0.4cm2 corresponds to severe MR. 
2.4.4.3 Pulmonary vein (PV) flow 
The pulmonary vein flow (Figure 4a) was sampled by the pulsed-Doppler technique. Images 
were obtained in the apical four-chamber view with transducer angulation to optimally visualize 
the right upper lobe pulmonary veins as they entered the left atrium. The systolic (S), diastolic 
(D) and atrial (a) waveforms were measured. Systolic pulmonary vein flow is reduced by 
increased transmitral flow in mitral regurgitation (Figure 4b) 41. Pulmonary venous systolic flow 
reversal was therefore considered an index of severe MR. 
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Figure 4: Pulmonary vein flow 
a) Normal pulmonary vein flow 
'---r-I '-r' 
Systole Diastole 
b) Pulmonary vein flow in mitral regurgitation 
MA 2+MR 3+MR 4+MR 
Blunting of the systolic wave (8) and dominance of the diastolic wave (D) 
2.5. Tissue Doppler imaging (TDI) 
Tissue Doppler Imaging (TDI) was performed with transducer frequencies of 1.8-3.6 MHz with 
minimum optimal gain as possible to obtain the best signal to noise ratio. In the apical four 
chamber view, a 5 mm pulsed Doppler sample volume was placed at the level of the lateral mitral 
annulus. The incident angle between the interrogating Doppler beam and longitudinal motion of 
the ventricle was kept as small as possible. The myocardial systolic wave (Srn) velocity, the 
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diastolic indices viz early myocardial (Em) and atrial contraction (Am) peak velocities, Em:Am 
ratio, and the Em/Ea ratio were measured. Pulse wave (PW) measurements of the mitral E and A 
wave velocity across the mitral valve were made in the apical 4-chmaber view, with the sample 
volume placed just beyond the MV leaflet tips. The ratio of the mitral E wave to the annulus E 
wave on tissue Doppler was used as an estimate of the L V filling pressure (Figure 5). 




Mitral annular velocity 
Tissue dOl?pler 
2.6. Measurement of Brain natriuretic peptide levels (NT -proBNP) 
Venous blood samples were taken in gel-filled tubes with the patient resting quietly while semi-
recumbent at the time of echocardiography. A baseline sample was taken from all subjects, and 
further samples were taken from subjects undergoing mitral valve replacement at I-week and 6-
weeks post surgery. 
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The samples were taken and centrifuged within 20 min at room temperature. The plasma was 
stored at -20°C and NT -proBNP was assayed in batches by standard electrochemiluminescence 
immunoassay ("ECLIA") using the Modular Analytics E170 (ELECYS module) and Elecsys 
101012010 analyzer (Roche diagnostics). 
Samples from cases and controls were stored for the same duration and were handled together, 
identically. Resting BNP values considered normal for this methodology lie below 100 pg/mL 
(l1.8pmolll for NT -proBNP) 42. The within-assay and total precision coefficients of variation for 
NT- proBNP (mean 208 pmol/l) is 0.8% and 4.5% respectively. The Reading sensitivity is 
between 0.6-4130 pmolll and 5-35000 pg/ml. The functional sensitivity is <5.9pmol/1. 
To convert natriuretic peptide levels expressed in pmol/l to pg/ml, multiply by 8.46 for NT-
proBNP, and to convert from pg/ml to pmol/l, multiply by 0.118. 
2.7. Statistical analysis 
SPSS for Windows, version 13.0 was the program used for the statistical analysis. Results are 
presented as mean +/- SD or percentages. Clinical variables were normally distributed and 
expressed as mean ± SD. BNP levels were not normally distributed and were therefore log-
transformed for statistical analysis. Group comparisons were performed with Analysis of 
Variance (ANOV A), t-test or chi-square test as appropriate. Associations of baseline NT-
proBNP were tested with linear and non-parametric regression (categorical variables) 
Multivariate analysis with stepwise multiple linear regression was used to define independent 
determinants of NT - proBNP levels. The time course of NT - proBNP within the cases was 
evaluated using paired t-tests. The discriminating capacity of the NT - proBNP for separating 
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surgical cases from controls was assessed by the construction of Receiver Operator Curves 
(ROC) curves. 
2.8.Intra-observer-variability 
The intra-observer variability for the measurements of PIS A and TDI was <5% . 




A total of 55 patients with severe mitral regurgitation were emolled in the study and surgical 
cases were followed up for six weeks. Their baseline characteristics are shown in Table 1. 
3.2. Baseline demographic Data 
All but one of the patients in our study population was of African descent (98%). In the study 
group, there were seven males and twenty females with a mean age of 20 years, all with a 
rheumatic aetiology. There was no significant difference between the 2 groups for age, gender or 
EF (Table 1). There were 28 control patients who were studied from the cardiology follow-up 
clinic, all with severe rheumatic mitral regurgitation, except one patient who was subsequently 
found to have ischaemic aetiology. 
Patients in the study group were more symptomatic with a predominance of patients in the study 
group (59%) that had an NYHA classification of 3-4 vs 11 % patients in the control group (Table 
1). Clinical heart failure was diagnosed in 4 patients in the study group. Both groups had an 
almost equal number of patients on diuretic therapy. Atrial fibrillation (AF) was present in 10 
patients in the study and 6 patients in the control group. 
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Table 1: Patient demographics and Clinical Findings 
Age 28 
MaleslFemales 7/21 7/20 0.937 
NYHA: i-ii 25 11 
NYHA iii-iv 3 16 0.001 
EF 65 ± 10* 67±7* 0.686 
Diuretics 25 21 
ACE inhibitors 25 25 
Atrial Fibrillation 6 10 
Aetiology: Rheumatic 27/28 27/27 
*mean±SD 
3.3. Pre-operative data 
By design all patients had severe mitral regurgitation as assessed clinically and this was 
confirmed on echocardiography. Although both control and study groups were equally matched 
in terms of having severe MR (EOA > 0.35cm2, regurgitant fraction (RF) and regurgitant volume 
(RV) of greater than 60% and 60ml respectively) the regurgitant fraction was greatest in the 
study group (Table 2). 
The number of patients with atrial fibrillation and a pulmonary artery (P A) systolic pressure of> 
60mmHg were marginally greater in the study group (p=ns). The P A systolic pressure was 
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elevated in all patients. Significant elevation of the P A pressure was present in seventeen patients 
in the control and twenty-two in the study group. Only one patient in the control group had 
markedly elevated systolic pressure (63mmHg) with an NYHA classification of 3. This patient 
subsequently had a valve replacement seven months after her evaluation. 
Table 2: Baseline quantification of severity of MR 
RF: 60-70% 8 2 
70-80% 14 4 
>80% 3 21 
RV>60ml 27 27 
EOA> 0.35 27 27 
PAS > 60mmHg 1 4 
40-49 mmHg 16 18 
30-39 mmHg 11 5 
Dominant diastolic flow (PWD) 25 24 
LA size: < 40mm 4 0 
40-49mm 4 2 
>49mm 20 25 
Systolic flow reversal (colour)** 27 27 
Jet density: 50-70% of inflow* 28 27 
* Intensity of MR Doppler jet in relation the injlow 
** Pulmonary veinjlow reversal as determined by colour Doppler 
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There were no significant differences between the 2 groups for L V dimensions, but the LA size 
and volume were increased in the study as compared to the control group. (p<O.OOl and p = 
0.002 respectively). There was a trend towards slightly higher end-systolic dimensions in the 
study group. 
The systolic wave on tissue Doppler was similar in both groups (Table 3: p=ns). The Doppler 
early diastolic filling ratios (mitral/ annulus) was elevated in both groups (> 1 0) and was 
markedly higher in the study group (p= 0.04), indicating high LV filling pressures. Likewise a 
similar pattern was observed with NT-proBNP which was elevated in both groups, and was 
markedly elevated in the study group (262 ± 224) Table 3: p<O.OOl. 
Table 3: Pre-operative evaluation 
59±13 76±16 <0.001 
LA volume (ml) 174.1 ± 118 309± 183 0.002 
EDV (ml) 177 ± 69 165 ±48 0.465 
ESV (ml) 59±26 57±25 0.723 
EDD(mm) 63±10 67±8 0.051 
ESD (mm) 38±9 43±8 0.056 
TDI syst.(m/s) 0.097±0.03 0.1±0.03 0.36 
TDIEmlEa 14±8 20±8 0.04 
NT -proBNP (pmol/l) 57±87 262 ±224 <0.001 
All values shown as mean ± SD 
3.4. Time course patterns of surgical cases and controls 
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In the surgical cases NT-proBNP time-course patterns showed an initial increase at I-week after 
the operation (Figure 6). This was followed by a decrease at the 6-week follow-up visit to values 
similar to the control population group. A further decrease was documented in 2 patients at the 6-
month visit to below control population group. 
Figure 6: NT-proBNP time course patterns 
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As expected there was an initial increase in chamber size in patients from the study group who 
underwent surgical correction and a fall in ejection fraction immediately to a mean of 41 % after 
surgery (one week) (Table 4). This was followed by a decrease in all chamber sizes at 6-weeks 
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compared to the I-week evaluation. There was a significant increase in the ejection fraction at 6-
weeks which was accompanied by maintenance in the TDI-systolic wave. There were 
statistically significant changes in the LA dimension, end diastolic diameter of the left ventricle, 
ejection fraction and NT -proBNP levels. It is noteworthy that inasmuch as there was a slight 
reduction in the EDV and ESV, these changes were not statistically significant. Although the 
TDI systolic wave indices were unchanged between the 2 time points, there was a significant 
increase noted in the early diastolic filling ratios, suggesting a further rise in the left ventricular 
filling pressures at six weeks. 
Table 4: Post-operative data 
58±16 2.0,11.2 0.009 
LA(ml) 234±152 182±140 21.2,82.9 0.003 
EDV(ml) 139±52 125±55 -15.7,43.8 0.326 
ESV(ml) 86±47 73±47 -10.7,37.5 0.250 
EDD(mm) 59±9 54±8 2.4,10.2 0.004 
ESD(mm) 45.5±14 38.7±9 12.7, 1.0 0.03 
EF(%) 42±13 51±13 -17.9, -1.0 0.032 
395±460 94±161 87.5,514.1 0.009 
EmlEa(l) 12±4 15±3 -6.7, -0.2 0.418 
TDI- S-wave 0.07±0.16 0.07±0.15 -0.01, - 0.2 0.821 
Cl: confidence interval 
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In the immediate post-operative period, NT -proBNP levels rose from preoperative levels to a 
mean level of 395pmolll and thereafter subsided to 94pmolll at six weeks. These changes were 
mirrored by a significant reduction in the LA size and volume, as well as in the LV chamber 
dimension to the control population group level (Table 4). 
Table 5 shows the correlation between mean log NT -pro BNP levels and echocardiographic 
variables. NT-pro BNP levels were not normally distributed and were log-transformed for this 
comparison. There were weak correlations at I-week and stronger correlations at 6-weeks 
between log NT -proBNP levels and chamber dimensions (Table 5), with the strongest correlation 
observed between NT-proBNP and TDI- systolic wave. 
Table 5: Correlations between log NT -proBNP and Echocardiographic variables 
0.115 58 0.32 0.211 
4 
LA Vol (ml) 2 0.249 0.290 182 0.24 0.371 
34 
EDV (ml) 1 0.217 0.357 125 0.13 0.622 
39 
ESV (ml) 8 0.359 0.12 73 0.26 0.353 
EDD(mm) 5 0.306 0.177 54 0.47 0.058 
9 
ESD(mm) 4 0.164 0.6 39 0.336 0.220 
5 
EF(%) 4 -0.18 0.45 51 -0.15 0.554 
2 
TDI (systolic) O. 0.12 0.6 0.07 0.484 0.049 
07 
* Means shown for comparison 
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3.6. Discriminating capacity of Echo and NT -proBNP to distinguish cases from 
controls 
A receiver operator curve was constructed for all variables to assess the discriminating capacity 
of each variable to distinguish between surgical cases and controls (Figure 7). Although the ESD 
at the established cut-off of 45 mm had a high specificity of 81%, it had a low negative 
predictive value of 36% (table 6). Of all the parameters studied the area under the ROe curve 
was greatest for NT -proBNP. 
Figure 7: Receiver Operator Curve- Surgical Cases and Controls 
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At the established the cut-off level of normality for BNP (12pmolll =125 pg/ml), NT-proBNP 
yielded the highest sensitivity of 96% and a specificity of 45% (Table 6). Using cut-off criteria 
established by Januzzi et al 32 for the detection of heart failure, at a level of 53 pmolll, the 
specificity for NT -proBNP improved to 74%, and the PPV to 84%. 
The two other established markers of systolic function namely, dP/dt and the TDI-systolic wave, 
had very low specificities and the TDI-systolic wave was elevated in all subjects, both in the 
study and control groups. 
Table 6: Published cut-offs versus study findings 




PPV: Positive predictive value, NPV: Negative predictive value 
* Cowie MR et al 43 
** Waggoner A67 
*** Choi YS28 
**** Bonow RO et ae6 
***** Chen Cet ae7 
Asterisks refer to published reference values with our values for comparison below. 
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A second Roe (Fig 8) was constructed using all the variables to separate NYHA class 1 and 2 
from 3 and 4. Once again, NT-proBNP emerged with the highest area under the curve. 
Figure 8: Receiver Operator Curve - NYHA all classes 
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3.7. Persistently elevated NT-proBNP levels at 6-weeks 
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Four patients showed persistently elevated NT-proBNP levels at 6-weeks compared to the other 
study cases (Table 7). Three patients had a large fall in the ejection fraction post-operatively, 
accompanied by minimal changes to pre-op ESD and NT -proBNP measurements (Table 7). In 
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these three cases_there was an increase in the diastolic filling ratios (EmJEa) and a decrease in the 
TDI-systolic wave. 
Two patients (cases 1 and 4 respectively) had a reduced EF < 60% (51% and 56% respectively) 
preoperatively associated with elevated NTproBNP postoperatively, suggesting that they had 
been operated upon quite late. As a result the first patient had a marked decline in ejection 
fraction postoperatively, while the fourth patient had a large drop in the NT-proBNP levels, 
accompanied by an increase in the TDI-systolic wave, in keeping with return of contractile 
functioI1:. 
All four of these patients had atrial fibrillation pr~operatively, which persisted at 6-weeks. These 
four were identified by NT-proBNP levels set by Januzzi ' s rule in criteria (450pg/ml) for the 
diagnosis of heart failure patients in the PRIDE study. 




This is one of the first studies to evaluate left ventricular function using newer modalities of 
measuring left ventricular (LV) function. This study examined 55 patients with severe mitral 
regurgitation and sought to determine the ability of conventional and newer parameters to 
independently identify the cases that went to surgery. The strength of this study lies in the fact 
the changes described in relation to surgery could be ascribed purely to the valve regurgitation 
and not to other confounding factors. In particular ischaemia could not be implicated in the 
explanation for these changes since all (but one) patients had a clear rheumatic aetiology for their 
valvular disease and were in an age and ethnic group in which ischaemic heart disease is rare. 
The clinicians used standard clinical criteria (physical examination, X-ray, ECG, conventional 
echocardiographic parameters ie ESD >45mm, EF<60%) 36 to decide on surgery. They were 
blinded to the Tissue Doppler Imaging and the NT -proBNP results. What is clear from this study 
is that the clinicians are using advanced symptomatology as the prime indictor for surgical 
intervention. This clearly emerged in the NYHA classification since more than half the patients 
who went to surgery were severely symptomatic on treatment. 
The two groups were matched for L V dimensions; although the LA size and volume were 
increased in the study as compared to the control group, the number of patients with very large 
left atria was similar. Despite the fact that all patients had severe mitral regurgitation as assessed 
clinically and this was confirmed on echocardiography, it is apparent that within this group there 
were gradations of severity with a significant number of the study patients having RF >80%. It is 
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clear that there were significant differences between the groups: the study group had larger atria 
with more elevated filling pressures as reflected by the TDI filling ratio and the NT -proBNP 
levels. The systolic wave on tissue Doppler, however, was similar in both groups in keeping with 
their ejection fraction levels. Together with the higher RF all this points to a worse degree of 
regurgitation in the study group. 
This one of the first studies to evaluate time course changes in LV function using newer 
modalities to assess LV function in a well-defined group of patients with MR. Data on the 
natural history have been confounded by the varying criteria in the evaluation of the severity of 
the MR and by the differing aetiologies included in the same study. Since the outcome of 
patients with MR may be influenced by the underlying disease process rather than the regurgitant 
severity interpretation of data becomes difficult. For instance, the outcome in patients with 
ischemic MR may be predominantly affected by the severity of CHD. We therefore excluded 
patients with ischaemia in this series and can confidently attribute the changes to the regurgitant 
lesion and to the underlying L V function, and not to ischaemia. There was one patient in the 
control group, however, that did have ischaemic MR. 
In this study of patients with rheumatic mitral regurgitation, we found that NT -proBNP levels 
were significantly increased in patients undergoing valve replacement surgery, as compared to 
control patients with similar degrees of mitral regurgitation. In this study we investigated NT-
proBNP because it has been shown to be a potential marker of left ventricular dysfunction and 
could predict diastolic abnormalities in patients with normal systolic function 44 as well as heart 
failure while limiting the need for expensive cardiac imaging modalities45, 46. Moreover, NT-
proBNP measurements provide prognostic information in patients with coronary heart disease 47; 
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48, and there is evidence that the pharmacotherapy for heart failure might be guided by plasma 
concentration ofNT -proBNP. 
It is now well established that the plasma level of BNP is elevated in patients with congestive 
heart failure and increases in proportion with the degree of left ventricular dysfunction and the 
. f fh rtC·l 49; 50 seventy 0 symptoms 0 ea lal ure . 
The increase in LV dimensions and fall in the EF in the early postoperative phase that we have 
documented is well described following mitral valve surgery for MR. Despite symptomatic 
improvement, postoperative left ventricular dysfunction (ejection fraction < 50%) is frequent, 
occurring in close to a third of the patients successfully operated upon for organic mitral 
. . 51 
regurgItatIOn. . 
In series of experiments in which high-fidelity measures of left ventricular contractility such as 
elastance were used, it was shown that left ventricular contractile dysfunction is present in many 
patients with severe MR despite a normal ejection fraction and that this returned to normal after 
corrective mitral valve surgery in some but not all patients 21. This was very apparent in all our 
patients. In fact, all our patients experienced a much higher drop than 10% in the EF immediately 
post surgery. This improved at the 6-week follow-up visit in all but 3 of our patients (11 %). The 
six-month evaluation will shed more light on the outcome of these patients: whether the LV 
dysfunction persists, and whether it is related to pre-operative echocardiographic and NT-
proBNP measurements in this population. 
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Postoperative left ventricular dysfunction is associated with diminished survival and a high 
incidence of heart failure; therefore, timing of the operation to immediately prior to the onset of 
LV dysfunction is critical in reducing the patients' risk of developing post-operative ventricular 
dysfunction. 
Previous studies have demonstrated a clear inverse relationship between the LV EF and NT-
proBNP levels after myocardial infarction (MI) or with cardiac failure 29. In the current study, we 
were able to confirm this inverse relationship between natriuretic peptide levels and the EF, and 
furthermore showed that levels subsided at the six week evaluation with an improvement in the 
EF. The correlations at I-week and at 6-weeks between NT -proBNP levels and chamber 
dimensions suggest that these changes are paralleled by changes in the NT -proBNP levels but 
not the TDI ratios, suggesting that most of the changes were related to corrections in volume and 
removal of the diastolic runoff in to the left atrium. 
In this study NT-proBNP yielded the highest predictive value for discriminating between study 
and controls with a sensitivity of 96%. The low specificity of 45% (based on the clinical 
assessment) indicates a high number of false positives, ie patients selected by NT-proBNP as 
requiring surgery when in fact they were still being followed up in the clinic on medical therapy. 
The ESD at the established cut-off of 45 mm for defining the need for surgery had a higher 
specificity of 81 %, but it had a low negative predictive value of 36% (Table 6). The two other 
markers of systolic function namely, dP/dt and the TDI-systolic wave, had very low specificities 
and the TDI-systolic wave was elevated in all subjects, both in the study and control groups. 
When we tried using a different cutoff point of 8.5cm/s, the specificity approached that of NT-
proBNP, but the sensitivity dropped from 96 to 64%. 
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These data indicate that clinicians are placing heavy emphasis on the history to detect the 
presence of significant symptomatology as a guide to surgical intervention. This has inherent 
limitation of subjectivity in defining significant valve-related symptoms. Indeed, when the 
second ROe was constructed using NYHA as the determinant, NT -proBNP again emerged as the 
strongest discriminator of advanced NYHA class. We believe that the high false positive rate 
with NT -proBNP suggest that many of the control subjects with symptoms actually require 
surgery, rendering them true positives. Waiting for more advanced symptoms or signs of early 
decline of left ventricular function is associated with a real risk of left ventricular dysfunction 
postoperatively, and cannot be defended unless the mitral regurgitation is not severe enough to 
warrant immediate surgery. In Westem series these patients would have been operated on much 
earlier since the underlying pathology is non rheumatic, lending a good chance for a successful 
valve repair and consequently a lower operative risk. 
Two studies in particular, both from the Mayo Clinic, have highlighted the poor outcomes in 
patients with severe MR who were managed conservatively rather than surgically. One of these 
studies, published in 1996, involved 229 patients with flail mitral valves where flail was used as 
a surrogate for severe MR in the pre-Doppler era 10. The 86 patients treated medically in this 
study had a much higher than expected mortality of 6% per year. At 10 years, the majority of 
these patients had experienced heart failure, and all but 10% had died or had undergone surgery. 
Surgery was an independent predictor of better survival in multivariate analysis in this 
retrospective study. In the second study, Enriquez-Sarano et al prospectively evaluated 456 
patients with chronic MR with quantitative MR techniques2o• Mortality was 22% at 5 years. A 
major independent determinant of survival was the quantitative severity of the MR assessed by 
regurgitant orifice area. They found that those patients with a regurgitant orifice area >=0.4 cm2 
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had a 5-year survival of 58%, which was inferior to that of a matched control population (78%). 
Surgical intervention was again a highly significant independent determinant of better survival. 
A recent study by Sutton et ai, found that there was no relation with LV dimensions or ejection 
fraction and NT-proBNP 52. In contrast, our study was able to demonstrate a significant 
correlation between NT-proBNP and the EDV at both assessment points after surgery, and a 
significant relationship with the EF at 6-weeks. In a study of 84 asymptomatic patients who 
underwent surgical correction for MR, Agricola et al 53 demonstrated that TDI systolic indices 
can predict postoperative left ventricular function. A noteworthy point is that the best outcome 
was observed in patients with an EF > 60% and an LV end systolic diameter < 45 mm 46. This 
was also noted in our study. Post-operatively, the changes in NT-proBNP levels were 
significantly correlated with the TDI- systolic wave (See Table 5). There was a decline in the LA 
size and ventricular dimensions. We believe that this is most likely related to the combined effect 
of the severity of regurgitation and declining L V function. 
A further possible explanation for the decline in LA size and NT -proBNP is that atrial myocytes 
synthesize NT -proBNP as well as ANP in response to the chronic increase in LA pressure54• 
Overall, the TDI-systolic wave of 0.06m1s, which has been previously used to rule out systolic 
dysfunction, had very low sensitivities in separating surgical cases from controls (see Figure7). 
An increase to 0.085m1s only marginally improved the specificity. From this data, we believe 
that perhaps different cutoff points should be used in determining impaired LV function, and 
those cut-points need to be determined with serial evaluations. 
Furthermore, an increased E/E(a) ratio (> 12) and elevated BNP (> 170pg/ml) have been shown to 
be to be useful parameters in identifying identify patients at heightened risk of developing 
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paroxysmal atrial fibrillation as well as reflect early left ventricular dysfunction in a population 
of hypertensive patients ss. In our study these levels were much higher, even in our control 
population (see Table 3); suggesting perhaps that our patients need to be evaluated earlier with a 
view to assessing their risk of developing AF or L V dysfunction. 
In this study NT -proBNP could not discriminate preoperatively between the four patients who 
showed persistently elevated levels at 6-weeks and the rest of the sample. As pointed out three 
patients had a large fall in the ejection fraction post-operatively, accompanied by minimal 
changes in pre-op ESD and NT -proBNP measurements. There was an increase in the diastolic 
filling ratios (Em/Ea) and a decrease in the TDI-systolic wave, all pointing to impaired 
ventricular function which no parameter could detect preoperatively. All four of these patients 
had atrial fibrillation preoperatively, which persisted at 6-weeks. 
Several early studies have found increased NT -proBNP concentrations in patients with mitral 
regurgitation but none of these distinguished patients with ischaemic regurgitation from those 
with non-ischaemic regurgitation. In a population-based study of elderly people living in 
Finland, N-terminal ANP was significantly increased in those with moderate or severe mitral 
regurgitation 56. A study of patients with suspected LV dysfunction also found an association 
between NT -proBNP and the severity of mitral regurgitation 57. Another small study found 
increased plasma BNP concentrations in patients with moderate or severe mitral regurgitation of 
mixed aetiology 58. None of these studies excluded or satisfactorily controlled for patients with 
angina pectoris, L V dysfunction secondary to myocardial infarction, or concomitant valve 
disease, and all used qualitative methods for assessing mitral regurgitation. 
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We therefore excluded patients with an ejection fraction lower than 50%, and patients with 
ischaemia in the study group. There was one patient, however, in the control group who did have 
ischaemic MR. Aside from this instance, all our patients had chronic, severe rheumatic mitral 
regurgitation. Further studies will be performed to determine the profile ofNTproBNP activation 
in mitral regurgitation of varying degrees of severity. Furthermore, we plan to study subgroups 
separately, in order to determine the time course of NT-proBNP in the different stages of MR 
with/without ischaemia, so that a natural history may be developed for each of these aetiologies. 
In this study, we used additional quantitative methods for assessment of the regurgitation 
severity, as opposed to qualitative methods in previous studies69. It was very interesting to see 
that the surgical group had a significantly higher number of patients with the regurgitant fraction 
of> 80% (see Table2). 
More recently Sutton et al S9 studied 49 patients with varying degrees of isolated mitral 
regurgitation due to degenerative or rheumatic disease and an ejection fraction of > 55%. 
Concentrations of NT -proBNP were increased as compared with controls. NT -proBNP levels 
correlated most closely with clinical and echocardiographic variables and was related to the 
severity of mitral regurgitation and left atrial dimension as well as age and sex. There was no 
relation with LV dimensions or ejection fraction but this may reflect the relatively narrow range 
ofL V function and the use of dimensions rather than volumes to assess L V size. 
The largest study yet published is that of Detaint et al 60 from the Mayo Clinic, who followed up 
a relatively unselected group of 124 patients with more than mild organic mitral regurgitation. 
Just over a third of their patients had severe mitral regurgitation. These authors found that 
symptoms, the presence of atrial fibrillation, and the extent of both atrial and ventricular 
remodelling were independently associated with higher BNP concentrations. The severity of 
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mitral regurgitation, although univariately associated with BNP concentrations, was not an 
independent predictor. Uniquely, their study examined outcome over a mean of 4.4 years. After 
age, sex, functional status, LV function, and severity of regurgitation were controlled for, BNP 
was independently predictive both of death and the combined end point of heart failure or death. 
The implication of these findings is that BNP is not just a marker for the severity of mitral 
regurgitation or a surrogate for symptoms. Rather, it seems to reflect the consequences of mitral 
regurgitation for the heart, including adverse clinical outcome. 
A limitation of our study is that we have not evaluated NT -proBNP in normal control subjects. 
We evaluated patients with severe MR followed up at the outpatient's clinic as control MR 
subjects, all of whom had baseline NT -proBNP values higher than that reported in normal 
subjects. Nor have we studied varying degrees of MR, including mild and moderate. In a study 
of 112 patients with different grades of MR., it was found that only LV ejection fraction (p = 
0.016) and moderate or severe MR (p = 0.023) were significantly associated with NT-proBNP 
after adjusting for clinical, hemodynamic, and echo cardiographic variables 61. 
It is apparent that most of the patients in this series had some degree of L V decompensation, as 
indicated by changes in the TDI ratio and the NT-proBNP levels, despite a preserved EF. In 
series of experiments in which high-fidelity measures of left ventricular contractility such as 
elastance were used, it was shown that left ventricular contractile dysfunction is present in many 
patients with severe MR despite a normal ejection fraction and that this returned to normal after 
corrective mitral valve surgery in some but not all patients 21. In our study we had 3 such 
patients, a high percentage (11 %) for a small series. There was no indication of difficulties with 
myocardial preservation to suggest this as the cause for the decline in postoperative EF by almost 
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30% form normal pre-operative levels. We have yet to see if the LV function improves at the 6-
month follow-up visit. 
This is one of the first studies to investigate NT -proBNP and LV function in relation to valve 
surgery. Two other studies have investigated BNP concentrations pattern following cardiac 
surgery with cardioplegic arrest and shown enhanced release of BNP after aortic unclamping and 
termination of cardio pulmonary bypass. Furthermore, besides iatrogenic cardioplegia, cardiac 
surgery involves other major stimuli such as anesthesia, sternotomia, post-operative 
hemodynamics, that could influence BNP levels in a non- specific way 62. 
Georges et al 63 studied the changes in BNP 12 hours post coronary bypass surgery, and 
suggested that myocardial ischemia was the cause of the compromised left ventricular function. 
They also showed that the stunned myocardium was associated with reduced myocardial 
contraction, increased ventricular pressure and secretion of BNP. They found that ANP and BNP 
concentrations were elevated when compared to either healthy subjects or coronary heart disease 
patients, whatever the valvular heart disease (mitral, aortic or tricuspid). The decrease in systolic 
function after surgery was ascribed to the lack of adequate myocardial preservation during 
surgery in early studies. Secondly, the loss of the low-impedance systolic runoff into the atrium 
exposes true ventricular state, increasing the ventricular afterload, unmasking pre-existing 
contractile dysfunction 64. Lastly it is now well established that the disruption of the chordal 
continuity with valve replacement leads to changes in ventricular geometry and impairment of 
systolic function. In our study we documented a significant fall in ejection fraction 
postoperatively in four patients. There was no evidence to suggest that any intraoperative 
complication could have accounted for the deterioration. Although we believe that that our 
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findings are consistent with changes suggesting that the operation itself contributed to cardiac J 
ischemia from aortic crossclamp and cardioplegic arrest after termination of CPB, there was no 
documentation to suggest this in the operation notes. In the fourth patient a likely explanation for 
the decline in L V function lies in the acute afterload changes on the left ventricle consequent 
upon removal of the regurgitant leak. In this patient there was evidence of improving ventricular 
contractility from the tissue Doppler and NT -proBNP values. 
The current European Society of Cardiology (ESC) guidelines recommend surgery in the 
asymptomatic patient when the EF falls to <60% and ESD>45mm. Furthermore, surgery is also 
recommended for patients with AF and PHT with preserved systolic function. There is evidence 
however, suggesting that a L VESD >40mm is more sensitive to contractile reserve and that its 
use as an indication for surgery leads to improved postoperative outcomes 16. 
Alternate proposed measures include an elevated end-systolic wall stress, an elevated exercise 
ESD, and EDD greater than 70mm, or an early systolic dP/dt less than 
1343mmHglsec as derived from the Doppler mitral regurgitantjet 68 . 
In our study, 11 patients in the control group and 18 patients in the study group had a dP/dt lower 
than 1343mmHg/s. What is very interesting is that the 3 patients (see Table 7) who had 





Long-term survival after mitral valve replacement has been poor, with reported 5-year survival 
rates between 50% and 85% 61 , 4. Survival is better in later studies, possibly related to 
improvements in surgical technique 13. It appears that the two most recognized key factors 
affecting survival after mitral valve surgery are timing of the operation, and preservation of the 
chordal apparatus. Improved survival has been documented when surgery is performed before 
the onset of L V contractile dysfunction. Both ventricular function and survival are improved 
when at least partial continuity between the mitral annulus and papillary muscles is maintained. 
These data provide compelling arguments for earlier and timeous operation in severe MR. The 
evidence to date points to the most favourable outcomes once symptoms develop or there is 
evidence of increasing LV dilatation. Both parameters reflect a combination of worsening 
regurgitation and the onset of L V dysfunction. 
In this study we have shown that patients with more advanced symptoms have a higher grade of 
severe MR and evidence of significant L V decompensation as indicated by markers of filling 
pressure ie NT -proBNP and ElEa. In fact NT -proBNP detected advanced disease in a significant 
number of control subjects designated as false positive against clinical criteria. The false positive 
rate of 55% suggests that NT -proBNP may actually be detecting early LV decompensation in 
less symptomatic patients. Although there was no significant difference between the study cases 
and the controls pre-operatively for LV dimensions or ejection fraction, there was a marked 
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difference in mean NT-proBNP levels in the two groups. The significant difference in the 
diastolic filling ratios suggests that the NT -proBNP might be detecting some level of LV 
decompensation. Because of the ethical issues in randomization, several other studies have 
adopted a similar approach to ours. Pillai et al70 showed that elevated NT -proBNP levels 
preoperatively was an indicator of underlying myocardial dysfunction, which was not evident by 
routine 2-D echo cardiography, and sadvocated preoperative assessment ofNT-proBNP levels to 
detect occult myocardial dysfunction. Two other studies examined patients with varying degrees 
of MR, and showed that changes in ventricular function occur early in the disease process, before 
they can be detected echocardiographically 35, 71. 
The lack of a difference in the LV chamber parameters between surgical and control groups in 
our study indicates an almost total reliance on advanced symptoms which is worrying, because 
symptoms sometimes manifest late in the course of the disease, and L V dysfunction may have 
already set in prior to the onset of symptom development. Furthermore, assessment of symptoms 
may be difficult in clinical practice. It is likely that in some patients, the symptoms might be as a 
consequence of severe MR, while others may be classified as asymptomatic because they 
undertake little activity or ignore subtle symptoms. 
The stimulus for NT -proBNP is any increase in intracardiac pressure, dilatation or ischaemia. 
The fact that patients sent to surgery had markedly elevated NT -proBNP levels, suggests that in 
this study, the clinical assessment was not satisfactory in determining the correct timing for 
surgery. In fact, based on these guidelines, our study shows that a portion of the population has 
already reached the stage where L V dysfunction was fairly advanced. 
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NT -proBNP levels subsided in the majority of our study cases at 6-weeks. However, our study 
suggests that its behaviour at the six-week follow-up visit may offer some prognostic 
information. Inasmuch as NT -proBNP was not able to predict who would fare well, as all our 
patients had markedly elevated NT -proBNP, where it remained elevated, there was persistent LV 
dysfunction. The implications of this pattern will be evaluated at the 6-month follow-up visit. 
Tissue Doppler systolic indices reflect the EF and are thus subject to the loading conditions
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. 
However, the relatively preload independent Doppler filling ratios were unhelpful, as they 
were elevatedfrom the onset in both groups. In fact, the increase in the Doppler filling ratios (see 
Table 4) at 6-weeks post surgery seems to reflect the lack of changes in the LVEDV and ESV. 
All these data allow the supposition that in the natural history of mitral regurgitation, a gradual 
increase occurs in NT-proBNP levels according to the evolution of the disease. For decision 
making in the management of patients, the absolute values in each evolution stage cannot be 
applied, because they are not known. Therefore serial estimations on patients with varying 
degrees of moderate and severe MR are needed to determine the time points at which the NT-
proBNP rises in each evolution stage of MR, to correlate the rise with severity and symptom 
development and finally, to gauge a NT-proBNP level that should lead to a consideration of 
surgical intervention. 
The dilemma has been defining the onset of contractile dysfunction in patients with MR, given 
the fact that the loading conditions are altered by the regurgitant lesion. The ideal measure of LV 
performance should accurately reflect contractility, regardless of loading conditions, and should 
be precise, reproducible and easily measured. The recommended clinical cut-offs which are 
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supposed to be closest to meeting these requirements (EF and end-systolic dimensions), may not 
appear to be very effective in detecting early LV dysfunction, and hence, the timing of surgery is 
difficult and often delayed. 
Our study suggests that severe MR and L V function are closely linked, and that it is difficult to 
tease out the relevant contributions of each. We feel that NT -proBNP is a composite marker that 
should become an integral part in the clinical evaluation of patients for surgery, since it is more 
objective in defining symptomatology, and furthermore, it reflects the culmination of the effects 
of mitral regurgitation on LV function. The degree of MR by itself is probably not suitable as the 
sole criterion, nor is the LV dimension, unless this is corrected for body surface area. Indeed, 
serial NT-proBNP may prove to be the most reliable indicator of the timing for surgery. 
We have shown that decision making regarding the timing of surgery in our patients occurs 
rather late in the course of the disease, exposing many patients to unnecessary morbidity and the 
risk of permanent L V decompensation. The implications of our findings are that NT -proBNP is 
not just a marker of the severity of MR, or an objective assessment of symptoms: in fact, it seems 
to reflect the consequences of severe regurgitation on the heart ie onset of L V dysfunction, and 
its accompanying sequelae (AF and pulmonary hypertension).We propose that NT-proBNP be an 
additional marker, particularly in less symptomatic patients, even if the EF is normal. In time, it 
may prove to be a composite marker for the assessment of LV decompensation. 
This study shows that in spite of its limitation as a load-dependent measure, with serial testing in 
a carefully monitored and screened population, that NT-proBNP identifies early decompensation 
in patients with apparently preserved ejection fraction in chronic, severe mitral regurgitation. It 
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supports the finding of Detaint et al in that BNP reflects the severe haemodymamic, ventricular 
and atrial consequences of MR. It should be considered in patients with severe organic MR to 
assist in clinical decision making, particularly in patients with severe MR who appears to have 
mild symptoms. 
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1. Informed Consent Form 
INFORMED CONSENT 
You have been asked to participate in a research study. 
You have been informed about the study by .. . ...... . , . .. .. .. ........ . . . 
The purpose of this study is to determine the function of your heart before and after your operation using ultrasound. In addition, an additional sample of blood will be taken from you to do a special test. This test will measure the level of Srain Naturetic Peptide (SNP) in your blood. It will tell us more about the state of your heart function and whether we need to modify your medication. 
We also want to see if the level of the SNP rises or remains the same after your operation (only if you are going for surgery). Therefore an additional blood sample will be taken from you at 1 week, six weeks and six months after the operation. 
You may contact the Medical Research Office at the Nelson R Mandela School of Medicine at 031-2604604 if you have questions about your rights as a research subject. 
Your participation in this research is voluntary, and you will not be penalized or lose benefits if you refuse to participate or decide to stop. 
If you agree to participate, you will be given a signed copy of this document and the participant information sheet, which is a written summary of the research. 
I hereby agree to participate in this test performed on me. This will be used in a study for research purposes. I am aware that the results ofthis study, including personal details regarding my sex, age, date of birth, initials and diagnosis will be anonymously processed into a study report. 
The research study, including the above information, has been described to me orally. I understand what my involvement in the study means and I voluntarily agree to participate. 
Ucelwe ukuba ube ngomunye ozosiza ngocwaningo lokwelapha. Unxusiwe ukuba ubengxenye nababye ngu ... ..... . ... .. . .... ... .... inhlosos yocwaningo ngukuthola izinga lesimo senhliziyo yakho, uma kuqhathaniswa ngaphambili nanemuva kokwelashwa nokuhlinzwa kusetshenziswa I-ultrasound. 
Kuzodingeka kuthahthwe elinye 'igazi kuwena' oluzosetshenziselwa ukucwaninga izinga le SNP egazini lakho. Kushintshwe indlela owelashwa ngayo. 
Kudingeka ulwazi lokuba izinga le SNP liyakhuphuka yini noma cha. 
Igazi lizodonswa kuwena emuva kwe-
1. sonto 
2. amasonto ayisithupha 
3. emva kwezinyanga eziyisithupha emvuva kokuhlinzwa 
Ungayicela incazelo ejulile e Nelson R Mandela School of Medice ngaloluhlelo (031-2604604). 
Uyacelwa, awuphoqekile ukuba ube kyongxenye yalolucwaningo, futhi ungeke ujesiswe noma uphuma phakathi nendawo. 
Ngiya.v.u~~ ~kuba yingxe~ye yalolucwaningo kimina. Loku kuzosetshensizwa njengocwaningo kwezemfundo. Ngiazi uk~thl Imtnlntngwane yaml esese emayelana nobulili bami, iminyaka yami igama lami nesimo sempilo yami aYlzuvezwa futhi izosetshenziselwa imfundo nje kuphela. 
Lolucwaningo sengitsheliwe ngawo futhi ukuthatha iqhaza kuwo kusho ukuthi ngiyavuma ukuba yingxenye yawo. 
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Patient: ________ _ KZ No., ____________ __ 
Signature of Patient Date 
Signature of Witness Date 
Signature of Translator Date 
PATIENT INFORMATION LEAFLET AND INFORMED CONSENT 
(patients going for surgery) 
Subject Initials: 
Subject Study Number: 
Study Title 
Timing of Mitral valve Surgery: a comparison of Tissue Doppler Imaging (TDI); Brain Naturetic Peptide ( BNP) and echocardiography 
Introduction 
This information leaflet is to help you decide if you would like to participate in this study which is being conducted for research purposes. Before you agree to take part in this study, you should fully understand what it entails. If you have any questions that are not fully explained in this leaflet, do not hesitate to ask. You should not agree to take part in this study unless you are completely happy about all the procedures involved. 
What is the purpose of the study? 
You have been diagnosed with severe mitral regurgitation (leaking valve), and therefore, we would like you to consider taking part in this study. 
The purpose of this study is to determine the function of your heart before and after your operation using ultrasound. In addition, we would like to take a sample of blood from you to do a special test. This test will measure the level of BNP in your blood. It will tell us more about the state of your heart function and whether we need to modify your medication. 
We also want to see if the level of the BNP rises or remains the same after your operation. Therefore an additional blood sample will be taken from you at 1 week, six weeks and six months after the operation. 
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What are my rights as a participant in this study? 
Your participation in this study will be entirely voluntary and you can refuse to participate or stop at any time without stating any reason. The investigator retains the right to withdraw you from the study if it is considered to be in your 
best interest. 
What are the risks involved in this study? 
There are no risks involved, as we will be scanning you on a routine basis. The BNP blood sample will be taken when the routine bloods are taken. When you come to clinic for your routine follow-up, a registered phlebotomist will take an extra sample of blood. (about a tablespoon full) for the BNP estimation. 
Confidentiality 
All the information obtained during the course of this study is strictly confidential. Reported data will not be including information that identifies you as a patient in the study. You will be informed of any finding of importance to your 
health. 
Has the study received ethical approval? 
The ethics committee of University of Natal: Nelson R Mandela School of Medicine. has approved this study 
PATIENT INFORMATION LEAFLET AND INFORMED CONSENT (for Control population) 
Subject Initials: 
Subject Study Number: 
Study Title 
The determinants in the Timing of Mitral valve Surgery: a comparison of TOI; BNP and conventional echocardiography 
Introduction 
This information leaflet is to help you decide if you would like to participate in this study which is being conducted for research ~urposes. Before you agree to take part in this study, you should fully understand what it entails. If you have a~y questrons that are not fully explained in this leaflet, do not hesitate to ask. You should not agree to take part in this study unless you are completely happy about all the procedures involved. 
What is the purpose of the study? 
You have been diagnose~ with mitral regurgitation (leaking valve)/ aortic regurgitation (leaking valve )/dilated heart and therefore, we would hke you to consider taking part in this study. 
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We would like to do an ultrasound of your heart to assess the function of your heart. In addition, we would like to take 
a sample of blood from you to do a special test. This test will measure the level of BNP in your blood. It will tell us 
more about the state of your heart function and whether we need to modify your medication. 
What are my rights as a participant in this study? 
Your participation in this study will be entirely voluntary and you can refuse to participate or stop at any time without 
stating any reason. The investigator retains the right to withdraw you from the study if it is considered to be in your 
best interest. 
What are the risks involved in this study? 
There are no risks involved, as we will be scanning you on a routine basis. The BNP blood sample will be taken when 
the routine bloods are taken. When you come to clinic for your routine follow-up, a registered phlebotomist will take 
another sample of blood. 
Confidentiality 
All the information obtained during the course of this study is strictly confidential. Reported data will not be including 
information that identifies you as a patient in the study. You will be informed of any finding of importance to your 
health. 
Has the study received ethical approval? 
The ethics committee of University of Natal : Nelson R Mandela School of Medicine. has approved this study 
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2. Mitral Regurgitation Index: Grading of Its Six Constituent Variables 
1) Jet Penetration: 
0= no jet 
1 = central jet; jet does not impinge on lateral wall in any view 
2 = eccentric jet which extends up to the first pulmonary vein 
3 = eccentric jet which encircles the atrium extending beyond the pulmonary vein 
2) PISA: 
o =No PISA 
1 = PISA :::;0.5 cm 
2 = PIS A = 0.5-1.0 cm 
3 = PISA 2:1.0 cm 
3) CW Jet Intensity and Character: 
O=Nojet 
1 = Incomplete jet envelope 
2 = Complete jet envelope; jet density 20-50% of inflow 
3 = Complete envelope; jet density 50-70% of inflow 
4) Pulmonary Artery Pressure (PAP)*: 
o = PAP <25 mm Hg 
1 = PAP = 25-30 mm Hg 
I 
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~ = PAP = 31--45 mm Hg 
3 = PAP >45 mm Hg 
5) Pulmonary Venous Flow Pattern: 
o = systolic dominant flow; systolic impulse exceeds diastolic impulse by 50% or more 
I = systolic dominant flow; systolic impulse exceeds diastolic impulse by <50% 
2 = diastolic dominant flow 
I 
3 = systolic flow reversal 
6) Left Atrial Size: 
0= normal 
2 = mild enlargement 
2 = mild to moderate and moderate enlargement 
3 = moderate to severe and severe enlargement 
MR INDEX = Total Score/number of variables. 
PISA = proximal isovelocity surface area. 
